电邮这篇文章 Current approach to adjuvant therapy for breast cancer (a review)
- 作者: Conte P.1, Guarneri V.1
-
隶属关系:
- Университетская клиника г. Падуя, Италия
- 期: 卷 15, 编号 1 (2013)
- 页面: 12-18
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26879
- ID: 26879
如何引用文章
全文:
详细
The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer.
作者简介
PierFranco Conte
Университетская клиника г. Падуя, Италия
Valentina Guarneri
Университетская клиника г. Падуя, Италия
参考
- Globocan 2008. http://globocan.iarc.fr/factsheets/cancers/breast.asp
- Статистика злокачественных новообразований в России и странах СНГ в 2010 г. Под ред. акад. РАН и РАМН М.И.Давыдова, д-ра биол. наук Е.М.Аксель. М., 2012.
- Autier P et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011; 343: d4411.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta - analyses of long - term outcome among 100 000 women in 123 randomised trials EBCTCG. Lancet 2012; 379: 432–44.
- Dowsett M et al. Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. JCO, 2010; 28 (3): 509–18.
- Mouridsen H et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. The BIG 1–98 Collaborative Group. N Engl J Med 2009; 361: 766–76.
- Goss P et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early - stage breast cancer. N Engl JMed 2003; 349: 1793–802.
- Piccart-Gebhart М. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72.
- Romond Е.Н. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673–84.
- Slamon D et al. Phase III trial comparing ACT with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: Second interim efficacy analysis. Presented at the 2006 San Antonio Breast Cancer Symposium, San Antonio, TX.
- Smith I et al. 2-Year follow - up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29–36.
- Perez EA et al. on behalf of NCCTG, ECOG, SWOG, CALGB. Further analysis of NCCTGN9831, May 2005 update. Slide presentation presented at the 45th annual meeting of the American Society of Clinical Oncology, Orlando, FL, USA, May 13–17, 2005.
- Joensuu et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–20.
- Spielmann M et al. 3-year follow - up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. San Antonio Breast Cancer Symposium 2007.
- Moja L et al. Trastuzumab containing regimens for early breast cancer (Review). The Cochrane Library 2012; Is. 4.
- Keefe D. Trastuzumab - associated cardiotoxicity. Cancer 2002; 95 (7): 1592.
- Perez E.A., Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22 (2): 322.
- Fiuza M. Cardiotoxicity associated with trastuzumab treatment of HER2+-breast cancer. Adv Ther 2009; 26 (Suppl. 1): s9.
- Pivot X et al. PHARE trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. 2012 ESMO Congress. Abstr. LBA5 2012.
- Goldhirsch A et a. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. ESMO Congress Abstracts 2012: LBA6.
- NCCN Сlinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer version 3, 2013.
- Ismael G et al. Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2013; 13 (9): 869–78.
- SafeHer NCT 01566721. A phase III prospective, two - cohort non - randomized, multi - centre, multinational, open label study to assess the safety of assisted and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable HER2-positive early breast cancer. http://clinicaltrials.gov/show/NCT01566721
- Pivot X et al. Patient preference for subcutaneous vs intravenous adjuvant trastuzumab: results of the PrefHer Study. SG-BCC 2013; p. 207.
补充文件
